Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Issa F Khouri

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 2, 2019
Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell TransplantationDavid M Cordas Dos Santos, Rima M Saliba, Romil Patel, et al.
Blood|April 16, 2008
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximabIssa F Khouri, Peter McLaughlin, Rima M Saliba, et al.
Cancer|June 17, 2021
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisKoji Sasaki, Hagop M Kantarjian, Kiyomi Morita, et al.
Bone Marrow Transplantation|January 5, 2021
Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHDRohtesh S Mehta, Roland Bassett, Gabriela Rondon, et al.
American Journal of Hematology|February 24, 2024
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trialIssa F Khouri, Kamal Alzahrani, Hagop Kantarjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous TransplantIssa F Khouri, Denái R Milton, Alison M Gulbis, et al.
Acta Haematologica|July 1, 2020
Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid LeukemiaAmanda L Olson, Rima M Saliba, Betul Oran, et al.
Blood|May 16, 2012
Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year resultsIssa F Khouri, Rima M Saliba, William D Erwin, et al.
Blood Advances|September 13, 2018
Is a matched unrelated donor search needed for all allogeneic transplant candidates?Stefan O Ciurea, Maria Cecilia Borges Bittencourt, Denái R Milton, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomographyChelsea C Pinnix, Bouthaina Dabaja, Mohamed Amin Ahmed, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 2, 2019
Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell TransplantationDavid M Cordas Dos Santos, Rima M Saliba, Romil Patel, et al.
Blood|April 16, 2008
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximabIssa F Khouri, Peter McLaughlin, Rima M Saliba, et al.
Cancer|June 17, 2021
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisKoji Sasaki, Hagop M Kantarjian, Kiyomi Morita, et al.
Bone Marrow Transplantation|January 5, 2021
Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHDRohtesh S Mehta, Roland Bassett, Gabriela Rondon, et al.
American Journal of Hematology|February 24, 2024
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trialIssa F Khouri, Kamal Alzahrani, Hagop Kantarjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous TransplantIssa F Khouri, Denái R Milton, Alison M Gulbis, et al.
Acta Haematologica|July 1, 2020
Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid LeukemiaAmanda L Olson, Rima M Saliba, Betul Oran, et al.
Blood|May 16, 2012
Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year resultsIssa F Khouri, Rima M Saliba, William D Erwin, et al.
Blood Advances|September 13, 2018
Is a matched unrelated donor search needed for all allogeneic transplant candidates?Stefan O Ciurea, Maria Cecilia Borges Bittencourt, Denái R Milton, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomographyChelsea C Pinnix, Bouthaina Dabaja, Mohamed Amin Ahmed, et al.
Pageof 7